France Archives

News and Trends 22 Oct 2015

This €200M French Biotech uses Red blood Cells to Fight Leukemia & Pancreatic Cancer

Lyon’s Erytech (France) is a clinical biopharma working on improving its red blood cell transported drug, targeting cancers such as acute lymphocytic leukemia (ALL) and pancreatic adenocarcinoma. Now phase I/II trials for its GRASPA therapy have demonstrated good efficacy and safety. Circulating asparagine is needed by cancer cells to grow and proliferate. Erytech’s platform uses […]

October 22, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 21 Oct 2015

CAR-T Wannabe? Immuno-oncology Start-up snowballs $102M for Series A Fund

Gritstone Pharmaceuticals is a US start-up which will focus on R&D of its new CAR-T cancer therapy technique: tumor-specific neo-antigen (TSNA). An impressive financial syndicate is backing its launch this month, having achieved a £102M series A pot for their lung cancer research. This cash is a clear indication that this start-up has the 3 […]

October 21, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 21 Oct 2015

The SuperBones; Polymeric Smart Coating Strategy for Titanium Implants

Uppsala University (Sweden) in joint collaboration with Neutron-Scattering experts at the Institute of Laue-Langevin in Grenoble (France) will change the medical world of implants. A new growth-stimulating ‘gel’ will therefore help the body adopt such implants as its own – as man and machine merge! Welding artificial hip joints or making dental implants from titanium […]

October 21, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 20 Oct 2015

Scaling-up Biofuels: The Challenges of Giant Bioreactors

Global Bioenergies from France is building a proto-plant for Isobutene production in Germany, with partnerships with car manufacturer Audi. Now their plant will receive a 5,000 Litre fermentation tank, after overcoming the challenging process of scaling-up second generation biofuel production. Global Bioenergies’ return to first generation biofuel production has already been discussed as a bit […]

October 20, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 14 Oct 2015

Innate Pharma receives $5M from its Monster-deal with BMS

This milestone payment from Bristol-Myers Squibb is part of the lirilumab licensing agreement, the monster immuno-oncology deal of €408M ($465M) signed in July 2011. This payment was triggered by the dosing of the first patient in a phase II trial of the monoclonal antibody drug lirilumab, in combination with rituximab in patients with relapsed/refractory or […]

October 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 12 Oct 2015

Roche dishes out €509M for a Humanized antibody against Rheumatoid Arthritis

Adheron Therapeutics is a small California (US) biotech which has developed a phase I monoclonal antibody (mAb) therapy for inflammatory diseases such as Rheumatoid Arthritis. Using the mAb humanisation platform licensed from Abzena (a life Sciences group from Cambridge, UK), Adheron Therapeutics will now be acquired by Swiss giant Roche for €509M. Abzena, based in […]

October 12, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 9 Oct 2015

Biotech of the week: Enterome, the Leading French Microbiome Start-up

This week we’ve left the sunny Portuguese coast behind us and arrived in the ‘City of Lights’, Paris. The capital city of France is famous for the Eiffel Tower, fashion and cuisine but what you may not know it is home to Enterome Bioscience, a pioneer in personalized therapies that focus on microbiome related diseases. […]

October 9, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 7 Oct 2015

French Government launches a €100M Biotech Fund, Political Nonsense or Wise Investment?

French Health Minister Marisol Touraine visited Eligo Biosciences on Monday, one of the most promising French Biotechs start-ups. Co-founded by young bio-entrepreneurs Xavier Duportet, they inaugurated their brand new office space at Paris’ Institut Pasteur (See our exclusive interview with Duportet here: ‘Meet Eligo’, the Startup which Raised €2M to Redefine Antibiotics using CRISPR’). For the opening, […]

October 7, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 6 Oct 2015

Ancient Microalgae hold the Crucial gene needed for the Evolution of Plants to Land

Microalgae proves to possibly be the oldest organism exploited by the Biotech industry. Now a mass research collaboration from Wisconsin (US), Cologne (Germany), Toulouse (France) and Norwich (UK) amongst others have published in PNAS that the microalgal genes needed for bacterial and fungal symbiosis were originally present before the transition of ancient plants to land. […]

October 6, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 6 Oct 2015

An Insider’s experience at the iGEM Giant Boston Jamboree 2015

Last week, our Guest blogger Matthieu de Costa (LinkedIn here) attended the iGEM Giant Jamboree at the Hynes Convention Center in Boston (MA). As part of the IONIS iGEM Team from the Sup’Biotech Institute for Biotechnology in Paris (France), his team came back with a Gold medal for their Bio-console video game which aims to […]

October 6, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 5 Oct 2015

€31M goes to a 15-month old Start-up tackling the leading cause of Dwarfism

TherAchon is a 15-month old start-up from the Nice area (France) which has attracted some serious US investors as of late, drawn by their pioneering protein therapy for Achondroplasia (the leading cause of Dwarfism). OrbiMed have now joined New Enterprise Associates and Versant Ventures in a €31 million series A pot for their pre-clinical candidate. […]

October 5, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 5 Oct 2015

Manfred Horst on MSD, Biosimilars, KEYTRUDA and his Company’s rich history

Manfred Horst is a Director Business Development Europe and working from an office at MSD France, the French affiliate of MSD which has its HQ in New Jersey (and is known as Merck & Co. in the US). MSD is one of the biggest pharmaceutical companies in the world with a 2014 revenue of €37.4Bn and €6.4Bn […]

October 5, 2015 - 6 minutesmins - By Julie Lellouche

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us